Cancers | Free Full-Text | HDAC Inhibitors in Acute Myeloid Leukemia
Ribonucleotide reductase inhibitors suppress SAMHD1 ara‐CTPase activity enhancing cytarabine efficacy | EMBO Molecular Medicine
Molecular Targeting and Rational Chemotherapy in Acute Myeloid Leukemia. - Abstract - Europe PMC
Biomedicines | Free Full-Text | Understanding Failure and Improving Treatment Using HDAC Inhibitors for Prostate Cancer
Valproic acid enhances the antileukemic effect of cytarabine by triggering cell apoptosis
2'-Fluoro-2'-deoxy-ara-C(Bz)-3'-phosphoramidite | Cytidine Analog | MedChemExpress
Structural insights into HDAC6 tubulin deacetylation and its selective inhibition | Nature Chemical Biology
Panobinostat Enhances Cytarabine and Daunorubicin Sensitivities in AML Cells through Suppressing the Expression of BRCA1, CHK1, and Rad51 | PLOS ONE
IN ACUTE MYELOID LEUKEMIA, THE USE IN INDUCTION OF STANDARD DOSE ARA-C IS ASSOCIATED WITH A BETTER QUALITY OF RESPONSE AS COMPARED TO AN INDUCTION REGIMEN. - ppt download
Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia | Blood Cancer Journal
IN ACUTE MYELOID LEUKEMIA, THE USE IN INDUCTION OF STANDARD DOSE ARA-C IS ASSOCIATED WITH A BETTER QUALITY OF RESPONSE AS COMPARED TO AN INDUCTION REGIMEN. - ppt download
Romidepsin enhances the efficacy of cytarabine in vivo, revealing histone deacetylase inhibition as a promising therapeutic strategy for KMT2A-rearranged infant acute lymphoblastic leukemia | Haematologica
Targeting HDAC3, a new partner protein of AKT in the reversal of chemoresistance in acute myeloid leukemia via DNA damage response | Leukemia
Dissecting Histone Deacetylase 3 in Multiple Disease Conditions: Selective Inhibition as a Promising Therapeutic Strategy | Journal of Medicinal Chemistry
Frontiers | Increased HDAC Activity and c-MYC Expression Mediate Acquired Resistance to WEE1 Inhibition in Acute Leukemia
Frontiers | Recent Update of HDAC Inhibitors in Lymphoma
A Randomized Investigation of High-Dose Versus Standard-Dose Cytosine Arabinoside With Daunorubicin in Patients With Previously Untreated Acute Myeloid Leukemia: A Southwest Oncology Group Study - ScienceDirect
HDAC inhibitors promote granulocytic differentiation. (A)... | Download Scientific Diagram
A Randomized Comparison of Modified Intermediate-dose Ara-C versus High-dose Ara-C in Post-remission Therapy for Acute Myeloid Leukemia | Anticancer Research
![PDF] Panobinostat Enhances Cytarabine and Daunorubicin Sensitivities in AML Cells through Suppressing the Expression of BRCA1, CHK1, and Rad51 | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/f668094fba2a13c35b48a8e49e9586d85158d88a/11-Figure6-1.png "PDF] Panobinostat Enhances Cytarabine and Daunorubicin Sensitivities in AML Cells through Suppressing the Expression of BRCA1, CHK1, and Rad51 | Semantic Scholar")
PDF] Panobinostat Enhances Cytarabine and Daunorubicin Sensitivities in AML Cells through Suppressing the Expression of BRCA1, CHK1, and Rad51 | Semantic Scholar
A Randomized Comparison of Modified Intermediate-dose Ara-C versus High-dose Ara-C in Post-remission Therapy for Acute Myeloid Leukemia | Anticancer Research
Dissecting Histone Deacetylase 3 in Multiple Disease Conditions: Selective Inhibition as a Promising Therapeutic Strategy | Journal of Medicinal Chemistry
HDAC4 Governs a Transcriptional Program Essential for Synaptic Plasticity and Memory: Cell
HDAC deacethylation mechanism in leukemic cells . Overexpression of... | Download Scientific Diagram
Conserved in vitro expression of HDAC repressors and modulators of ARAC... | Download Scientific Diagram
The effects of cytarabine combined with ginsenoside compound K synergistically induce DNA damage in acute myeloid leukemia cells - ScienceDirect
RGFP966 Datasheet
